Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. (2016)

First Author: Ledermann JA
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(15)01167-8

PubMed Identifier: 27025186

Publication URI: http://europepmc.org/abstract/MED/27025186

Type: Journal Article/Review

Volume: 387

Parent Publication: Lancet (London, England)

Issue: 10023

ISSN: 0140-6736